Theravance Biopharma, Inc.
TBPH
$10.69
$0.080.75%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -58.33M | -56.42M | -49.40M | -45.65M | -44.77M |
| Total Depreciation and Amortization | 6.32M | 6.48M | 6.82M | 6.60M | 6.71M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 16.36M | 18.05M | 28.04M | 28.22M | 27.77M |
| Change in Net Operating Assets | 68.17M | 20.36M | 3.05M | 2.05M | -6.51M |
| Cash from Operations | 32.53M | -11.54M | -11.49M | -8.78M | -16.80M |
| Capital Expenditure | -241.00K | -332.00K | -819.00K | -825.00K | -1.64M |
| Sale of Property, Plant, and Equipment | -- | -- | 0.00 | 0.00 | 1.30M |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 26.13M | 12.62M | -3.26M | 14.12M | 27.72M |
| Cash from Investing | 25.89M | 12.28M | -4.08M | 13.30M | 27.38M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 627.00K | 607.00K | 617.00K | 592.00K | 619.00K |
| Repurchase of Common Stock | -2.26M | -3.10M | -33.36M | -64.37M | -145.03M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -1.64M | -2.50M | -32.74M | -63.77M | -144.41M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 56.78M | -1.75M | -48.31M | -59.25M | -133.83M |